BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22349923)

  • 1. The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
    Grossi F; Rijavec E; Dal Bello MG; Defferrari C; Brianti A; Barletta G; Genova C; Murolo C; Cosso M; Fontanini G; Boldrini L; Truini M; Pronzato P
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1407-12. PubMed ID: 22349923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib in advanced non-small-cell lung cancer after gefitinib failure.
    Zhou ZT; Xu XH; Wei Q; Lu MQ; Wang J; Wen CH
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1123-7. PubMed ID: 19322567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
    Cho BC; Im CK; Park MS; Kim SK; Chang J; Park JP; Choi HJ; Kim YJ; Shin SJ; Sohn JH; Kim H; Kim JH
    J Clin Oncol; 2007 Jun; 25(18):2528-33. PubMed ID: 17577030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.
    Kaira K; Naito T; Takahashi T; Ayabe E; Shimoyama R; Kaira R; Ono A; Igawa S; Shukuya T; Murakami H; Tsuya A; Nakamura Y; Endo M; Yamamoto N
    Lung Cancer; 2010 Apr; 68(1):99-104. PubMed ID: 19540616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment.
    Song ZB; Yu YF; Chen ZW; Lu S
    Chin Med J (Engl); 2011 Aug; 124(15):2279-83. PubMed ID: 21933557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
    Kim ST; Lee J; Kim JH; Won YW; Sun JM; Yun J; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2010 Jun; 116(12):3025-33. PubMed ID: 20564408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
    Hata A; Katakami N; Yoshioka H; Fujita S; Kunimasa K; Nanjo S; Otsuka K; Kaji R; Tomii K; Iwasaku M; Nishiyama A; Hayashi H; Morita S; Ishida T
    Lung Cancer; 2011 Nov; 74(2):268-73. PubMed ID: 21529987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer.
    Shao YY; Shau WY; Lin ZZ; Chen HM; Kuo R; Yang JC; Lai MS
    Eur J Cancer; 2013 Jan; 49(1):106-14. PubMed ID: 22897841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.
    Koizumi T; Agatsuma T; Ikegami K; Suzuki T; Kobayashi T; Kanda S; Yoshikawa S; Kubo K; Shiina T; Takasuna K; Matsuo A; Hayasaka M; Morikawa M; Ameshima S
    Clin Lung Cancer; 2012 Nov; 13(6):458-63. PubMed ID: 22402083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
    Zhou S; Ren S; Yan L; Zhang L; Tang L; Zhang J; Zhou C
    Respirology; 2009 Jul; 14(5):709-15. PubMed ID: 19659649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
    Wong AS; Soong R; Seah SB; Lim SW; Chuah KL; Nga ME; Chin TM; Soo RA
    J Thorac Oncol; 2008 Apr; 3(4):400-4. PubMed ID: 18379359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.
    Chen X; Li W; Hu X; Geng Y; Wang R; Yin Y; Shu Y
    Biomed Pharmacother; 2011 Dec; 65(8):542-6. PubMed ID: 21840160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
    Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
    Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
    Gridelli C; Maione P; Galetta D; Colantuoni G; Del Gaizo F; Ferrara C; Guerriero C; Nicolella D; Rossi A
    J Thorac Oncol; 2007 Aug; 2(8):758-61. PubMed ID: 17762344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months.
    Saito H; Murakami S; Kondo T; Oshita F; Noda K; Yamada K
    Onkologie; 2012; 35(1-2):18-22. PubMed ID: 22310340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
    Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
    Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
    Acharyya S; Sau S; Dasgupta P; Chakraborty A; Gangopadhyay S
    J Indian Med Assoc; 2012 Jul; 110(7):474-6, 493. PubMed ID: 23520673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.